Related Experiment Videos
[Systemic thrombolysis with short-term streptokinase infusion in acute myocardial infarct]
Insights
Brief high-dose intravenous streptokinase effectively restores blood flow in acute myocardial infarction patients, improving vessel patency and potentially salvaging heart muscle. Further trials are needed to confirm its impact on mortality and morbidity.
Area of Science:
- Cardiology
- Thrombolytic Therapy
Background:
- Acute myocardial infarction (AMI) requires prompt restoration of coronary blood flow.
- Intravenous streptokinase has been explored as a treatment option for AMI.
Purpose of the Study:
- To evaluate the efficacy of brief, high-dose intravenous streptokinase infusion in restoring blood flow and improving outcomes in patients with acute myocardial infarction.
Main Methods:
- 93 patients with AMI received either 500,000 IU or 1,500,000 IU of intravenous streptokinase within 30-60 minutes of symptom onset.
- Angiography was performed in the acute phase, at 24 hours, and/or at 4 weeks.
- Outcomes including vessel patency, stenosis, mortality, and reinfarction were assessed.
- A control group receiving no streptokinase was used for comparison.
Main Results:
- Reopening of occluded infarct vessels was achieved in 52% of cases within 1 hour of treatment initiation.
- By the 4th week, 84% of treated patients had a patent infarct vessel, with 58% having <70% stenosis, compared to 25% and 4% in the control group, respectively.
- Significant improvement in myocardial contractility and a correlation between infarct size and treatment timing were observed.
- Hospital mortality was 7.5% and nonfatal reinfarction occurred in 6.5% of treated patients, with no bleeding complications.
Conclusions:
- Brief, high-dose intravenous streptokinase effectively restores coronary blood flow in acute myocardial infarction.
- Early initiation of intravenous streptokinase may compensate for longer thrombolysis times compared to intracoronary administration.
- A conclusive randomized trial is necessary to definitively establish the impact of this treatment on mortality and morbidity in AMI.
Abstract:
Within 6 hours after the onset of acute myocardial infarction, 93 patients received a brief high-dose intravenous infusion of streptokinase, 49 patients received 500,000 IU within 30 min and 44 patients received 1,500,000 IU within 60 min. 26 patients had angiography in the acute phase, after 24 hours, and in the 4th week; 52 patients had angiography in the 4th week only; and 15 had no angiography. 7 patients died in hospital and 6 suffered a nonfatal reinfarction. There were no complications with bleeding. In 52% of cases, reopening of an occluded infarct vessel was achieved within 1 hour of the beginning of treatment. During the 4th week after infarction a patent infarct vessel was found in 84%, and 58% had a residual stenosis less than 70%. In contrast, in a control group that received no streptokinase treatment, 25% had a patent infarct vessel and 4% had a residual stenosis less than 70%. Indicative for salvage of ischemic myocardium are a significant improvement in local contraction disorders between the acute phase and the 4th week and a significant correlation between infarct size in the 4th week and beginning of treatment after onset of symptoms. 1. It may be concluded that: brief intravenous infusion of streptokinase results in restoration of blood flow in an infarcted coronary artery in a high percentage of cases; the shorter thrombus-lysis time with intracoronary streptokinase infusion could be made up for by the earlier initiation of intravenous streptokinase treatment; and a conclusive randomized trial is needed to ascertain the true impact of a brief high-dose intravenous infusion of streptokinase on mortality and morbidity following acute myocardial infarction.